These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 8527710)

  • 1. Efficacy of ursodeoxycholic acid in the treatment of patients with chronic hepatitis C.
    Lu CL; Chan CY; Hwang SJ; Lu RH; Lee SD
    J Gastroenterol Hepatol; 1995; 10(4):432-7. PubMed ID: 8527710
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of ursodeoxycholic acid in combination with interferon-alpha in treating chronic hepatitis C: results of a long-term follow-up trial.
    Tanaka K; Kondo M; Sakaguchi T; Saito S; Arata S; Ikeda M; Kitamura T; Morimoto M; Sekihara H
    J Gastroenterol Hepatol; 1996 Dec; 11(12):1155-60. PubMed ID: 9034935
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of ursodeoxycholic acid in association with alpha-interferon for chronic hepatitis C in alpha-interferon non-responder patients.
    Fabbri C; Marchetto S; Pezzoli A; Accogli E; Fusaroli P; Azzaroli F; Jaboli MF; Mazzeo C; Montagnani M; Festi D; Roda E; Mazzella G
    Eur J Gastroenterol Hepatol; 2000 May; 12(5):511-5. PubMed ID: 10833093
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term treatment of chronic hepatitis C with ursodeoxycholic acid: influence of HCV genotypes and severity of liver disease.
    Lirussi F; Beccarello A; Bortolato L; Morselli-Labate AM; Crovatto M; Ceselli S; Santini G; Crepaldi G
    Liver; 1999 Oct; 19(5):381-8. PubMed ID: 10533795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improvement of alanine aminotransferase by administration of suplatast tosilate plus ursodeoxycholic acid in patients with resistance to ursodeoxycholic acid monotherapy on hepatitis C virus-related chronic liver disease.
    Matsuda Y; Inada M; Maeda H; Matsuyama T
    Intern Med; 2002 Oct; 41(10):774-9. PubMed ID: 12412994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term efficacy of interferon-alpha and ursodeoxycholic acid in treatment of chronic type C hepatitis.
    Senturk H; Uzunalimoglu O; Batur Y; Simsek I; Mert A; Ozbay G; Cetinkaya H; Ersoz G; Tabak F; Akbaylar H; Akdogan M; Dokmeci A; Sonsuz A; Ozenirler S; Erden E; Tozum N
    Dig Dis Sci; 1997 Jul; 42(7):1438-44. PubMed ID: 9246043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interferon and ursodeoxycholic acid combined therapy in the treatment of chronic viral C hepatitis: results from a controlled randomized trial in 80 patients.
    Boucher E; Jouanolle H; Andre P; Ruffault A; Guyader D; Moirand R; Turlin B; Jacquelinet C; Brissot P; Deugnier Y
    Hepatology; 1995 Feb; 21(2):322-7. PubMed ID: 7843700
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ursodiol use is possibly associated with lower incidence of hepatocellular carcinoma in hepatitis C virus-associated liver cirrhosis.
    Tarao K; Fujiyama S; Ohkawa S; Miyakawa K; Tamai S; Hirokawa S; Masaki T; Tanaka K
    Cancer Epidemiol Biomarkers Prev; 2005 Jan; 14(1):164-9. PubMed ID: 15668491
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interferon plus ursodeoxycholic acid versus interferon in the treatment of chronic C viral hepatitis.
    Clerici C; Distrutti E; Gentili G; Solinas A; Miglietti M; Balò S; Giansanti M; Rusticali AG; Morselli-Labate AM; Morelli A
    Minerva Med; 1997 May; 88(5):219-25. PubMed ID: 9250283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of ursodeoxycholic acid therapy in chronic viral hepatitis C with high serum gamma-glutamyltranspeptidase levels.
    Kiso S; Kawata S; Imai Y; Tamura S; Inui Y; Ito N; Matsuzawa Y
    J Gastroenterol; 1996 Feb; 31(1):75-80. PubMed ID: 8808432
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A large-scale, multicentre, double-blind trial of ursodeoxycholic acid in patients with chronic hepatitis C.
    Omata M; Yoshida H; Toyota J; Tomita E; Nishiguchi S; Hayashi N; Iino S; Makino I; Okita K; Toda G; Tanikawa K; Kumada H;
    Gut; 2007 Dec; 56(12):1747-53. PubMed ID: 17573387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant interferon-alpha and ursodeoxycholic acid versus interferon-alpha alone in the treatment of chronic hepatitis C: a randomized clinical trial with long-term follow-up.
    Angelico M; Gandin C; Pescarmona E; Rapicetta M; Del Vecchio C; Bini A; Spada E; Baroni CD; Capocaccia L
    Am J Gastroenterol; 1995 Feb; 90(2):263-9. PubMed ID: 7847298
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined ursodeoxycholic acid and glycyrrhizin therapy for chronic hepatitis C virus infection: a randomized controlled trial in 170 patients.
    Tsubota A; Kumada H; Arase Y; Chayama K; Saitoh S; Ikeda K; Kobayashi M; Suzuki Y; Murashima N
    Eur J Gastroenterol Hepatol; 1999 Oct; 11(10):1077-83. PubMed ID: 10524635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Comparison on the efficacy and safety of biphenyl dimethyl dicarboxylate and ursodeoxycholic acid in patients with abnormal alanine aminotransferase: multicenter, double-blinded, randomized, active-controlled clinical trial].
    Lee SH; Cheon GJ; Kim HS; Kim YD; Kim SG; Kim YS; Jeong SW; Jang JY; Kim BS
    Korean J Gastroenterol; 2014 Jul; 64(1):31-9. PubMed ID: 25073669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of combination therapy of interferon-alpha with ursodeoxycholic acid in chronic hepatitis C: a randomized controlled clinical trial.
    Kiso S; Kawata S; Tamura S; Imai Y; Inui Y; Nagase T; Maeda Y; Yamasaki E; Tsushima H; Igura T; Himeno S; Seki K; Matsuzawa Y
    J Gastroenterol; 1997 Feb; 32(1):56-62. PubMed ID: 9058296
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of interferon, ribavirin and ursodeoxycholic acid in patients with hepatitis C infection.
    Ljubuncic P; Konikoff FM; Blendis LM; Bomzon A
    Hepatogastroenterology; 2005; 52(64):1191-6. PubMed ID: 16001659
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation of serum HCV RNA and alanine aminotransferase levels in chronic hepatitis C patients during treatment with ribavirin.
    Tong MJ; Hwang SJ; Lefkowitz M; Lee SD; Co RL; Conrad A; Schmid P; Lo KJ
    J Gastroenterol Hepatol; 1994; 9(6):587-91. PubMed ID: 7865717
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A dose-up of ursodeoxycholic acid decreases transaminases in hepatitis C patients.
    Sato S; Miyake T; Tobita H; Oshima N; Ishine J; Hanaoka T; Amano Y; Kinoshita Y
    World J Gastroenterol; 2009 Jun; 15(22):2782-6. PubMed ID: 19522030
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of ursodeoxycholic acid on serum liver enzymes in patients with hepatitis C virus-related chronic liver disease.
    Puoti C; Magrini A; Filippi T; Annovazzi G; Pannullo A
    Eur J Gastroenterol Hepatol; 1995 Feb; 7(2):151-4. PubMed ID: 7712308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of ursodeoxycholic acid administration in patients with acute viral hepatitis: a pilot study.
    Fabris P; Tositti G; Mazzella G; Zanetti AR; Nicolin R; Pellizzer G; Benedetti P; de Lalla F
    Aliment Pharmacol Ther; 1999 Sep; 13(9):1187-93. PubMed ID: 10468700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.